-
-
-
-
-
-
-
Oncternal Therapeutics (ONCT) Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH
-
-
-
-
-
-
-
Form 4 Oncternal Therapeutics, For: Jul 21 Filed by: Shanghai Pharmaceutical (USA) Inc.
-
-
-
-
55,540 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All